Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (61-70 of 179) with videos related to

Pageof 18
Sort By:
Angewandte Chemie (International Ed. in English)|January 4, 2007
The structures and optical spectra of hydrated transplutonium ions in the solid state and in solutionPatric Lindqvist-Reis, Christos Apostolidis, Jean Rebizant, et al.
Biomaterials|April 3, 2017
Alpha-particle radiotherapy: For large solid tumors diffusion trumps targetingCharles Zhu, Michelle Sempkowski, Timothy Holleran, et al.
Cancer Research|March 3, 2007
Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cellsClaudia Friesen, Gerhard Glatting, Bernd Koop, et al.
Clinical Nuclear Medicine|February 28, 2023
Locoregional Treatment of Glioblastoma With Targeted α Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence ParametersLeszek Królicki, Jolanta Kunikowska, Frank Bruchertseifer, et al.
EJNMMI Physics|May 9, 2024
Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of glioblastomasMonika Tulik, Radosław Kuliński, Zbisław Tabor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2017
Targeted alpha therapy of mCRPC: Dosimetry estimate of <sup>213</sup>Bismuth-PSMA-617Clemens Kratochwil, Karl Schmidt, Ali Afshar-Oromieh, et al.
Cancer Research|November 19, 2009
Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90YHong Song, Robert F Hobbs, Ravy Vajravelu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2007
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imagingH Matthias Buchhorn, Christof Seidl, Roswitha Beck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 16, 2021
Dose escalation study of targeted alpha therapy with [<sup>225</sup>Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacyLeszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska, et al.
Nanomaterials (Basel, Switzerland)|October 23, 2020
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha RadioimmunotherapyWeronika Gawęda, Marek Pruszyński, Edyta Cędrowska, et al.
Pageof 18

Showing results (61-70 of 179) with videos related to

Sort By:
Pageof 18
Angewandte Chemie (International Ed. in English)|January 4, 2007
The structures and optical spectra of hydrated transplutonium ions in the solid state and in solutionPatric Lindqvist-Reis, Christos Apostolidis, Jean Rebizant, et al.
Biomaterials|April 3, 2017
Alpha-particle radiotherapy: For large solid tumors diffusion trumps targetingCharles Zhu, Michelle Sempkowski, Timothy Holleran, et al.
Cancer Research|March 3, 2007
Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cellsClaudia Friesen, Gerhard Glatting, Bernd Koop, et al.
Clinical Nuclear Medicine|February 28, 2023
Locoregional Treatment of Glioblastoma With Targeted α Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence ParametersLeszek Królicki, Jolanta Kunikowska, Frank Bruchertseifer, et al.
EJNMMI Physics|May 9, 2024
Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of glioblastomasMonika Tulik, Radosław Kuliński, Zbisław Tabor, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2017
Targeted alpha therapy of mCRPC: Dosimetry estimate of <sup>213</sup>Bismuth-PSMA-617Clemens Kratochwil, Karl Schmidt, Ali Afshar-Oromieh, et al.
Cancer Research|November 19, 2009
Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90YHong Song, Robert F Hobbs, Ravy Vajravelu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2007
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imagingH Matthias Buchhorn, Christof Seidl, Roswitha Beck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 16, 2021
Dose escalation study of targeted alpha therapy with [<sup>225</sup>Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacyLeszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska, et al.
Nanomaterials (Basel, Switzerland)|October 23, 2020
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha RadioimmunotherapyWeronika Gawęda, Marek Pruszyński, Edyta Cędrowska, et al.
Pageof 18